What is the JAK2 Mutation Assay?
The JAK2 mutation assay is a molecular diagnostic test that detects pathogenic mutations in the JAK2 gene—most commonly the V617F mutation in exon 14 and less frequently mutations in exon 12—to diagnose and classify Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. 1, 2
Clinical Purpose and Diagnostic Role
The JAK2 mutation assay serves as a major diagnostic criterion in the WHO classification system for MPNs, providing molecular proof that a proliferative process is clonal rather than reactive. 1
Key Mutations Detected
JAK2 V617F (c.1849G>T): The predominant mutation found in:
JAK2 exon 12 mutations: Identified in approximately 2-4% of JAK2 V617F-negative polycythemia vera patients, representing a rare but diagnostically critical subtype. 3, 6
When to Order the Test
Primary Indications
- Unexplained erythrocytosis: Hemoglobin >18.5 g/dL in males or >16.5 g/dL in females 2
- Persistent thrombocytosis: Sustained platelet count ≥450 × 10⁹/L 1, 2
- Suspected myelofibrosis: Constitutional symptoms, splenomegaly, cytopenias 4
- Splanchnic vein thrombosis: Particularly in younger patients without typical risk factors 7, 2
Testing Algorithm and Methodology
Recommended Testing Sequence
Step 1: Order JAK2 V617F testing first, as this is the most common mutation across all MPN subtypes. 2, 4
Step 2: If JAK2 V617F is negative but clinical suspicion remains high:
- For erythrocytosis: Test for JAK2 exon 12 mutations 2, 8
- For thrombocytosis or myelofibrosis: Test for CALR mutations first, then MPL mutations 2, 4
Technical Specifications
Sensitivity requirement: The assay must detect mutant allele burdens as low as 1-3% to avoid missing cases with low-level mutations. 2, 8
Preferred sample type for exon 12 testing: Use purified granulocyte DNA rather than whole blood, as granulocytes contain higher proportions of mutant alleles, improving detection sensitivity. 3, 2
Common methodologies:
- Allele-specific quantitative PCR (qPCR): Most prevalent method with excellent sensitivity 9
- High-resolution melting analysis 9
- Next-generation sequencing (NGS): Highly correlated with qPCR (R² = 0.9477) but with a higher detection limit of approximately 2%, making it less sensitive for low-burden mutations 9
Clinical Interpretation
Positive JAK2 V617F Result
A positive result eliminates consideration of a reactive process and confirms clonal proliferation, though it does not specify which MPN subtype is present. 1 Additional clinical, laboratory, and bone marrow histopathologic features are required for accurate subclassification. 1
Positive JAK2 Exon 12 Result
This confirms polycythemia vera in patients with erythrocytosis who are JAK2 V617F-negative. 1, 3 Bone marrow histology typically shows isolated erythroid hyperplasia without the panmyelosis seen in classic JAK2 V617F-positive disease. 3
Negative Results
- Approximately 10-15% of essential thrombocythemia and primary myelofibrosis cases are triple-negative (JAK2/CALR/MPL negative) but still represent true clonal MPNs based on bone marrow histology. 4
- Bone marrow biopsy becomes mandatory in triple-negative cases to evaluate for characteristic MPN histopathology. 4
Common Pitfalls and Caveats
False-Negative Results
- Low allele burden: Mutations present at <1-3% may be missed if the assay lacks adequate sensitivity. 8
- Wrong sample type: Whole blood testing for exon 12 mutations may miss low-burden mutations that would be detected in purified granulocytes. 3
- Testing only for V617F: Restricting testing to V617F alone will miss the 2-4% of polycythemia vera patients with exon 12 mutations. 3, 6
Interpretation Errors
- JAK2 mutation is not disease-specific: The V617F mutation can be found in polycythemia vera, essential thrombocythemia, and primary myelofibrosis, so clinical and histologic correlation is essential. 1
- Mutation does not equal diagnosis: Molecular results must be interpreted in the context of clinical findings, complete blood counts, and bone marrow histology. 8
Next Steps After Testing
Positive Result
- Refer to hematology for bone marrow biopsy and definitive MPN subtype classification. 2
- Initiate risk stratification based on age (>60 years) and prior thrombosis history. 3, 4